Jun282021 Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease Dementia June 28, 2021
May72021 Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit May 7, 2021
May52021 Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President for Nonclinical Development May 5, 2021
Feb82021 Anavex Life Sciences to Announce Fiscal 2021 First Quarter Financial Results and Business Outlook on Thursday, February 11, 2021 February 8, 2021
Jan112021 Anavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73 (blarcamesine) in People with Parkinson’s Disease January 11, 2021
Dec222020 Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020 December 22, 2020
Nov62020 Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 Conference November 6, 2020
Oct152020 Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia October 15, 2020
Apr232020 Anavex Life Sciences Announces Publication of Clinical Data for ANAVEX®2-73 (blarcamesine) in Alzheimer’s Disease April 23, 2020
Jan272020 Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Disease Dementia (PDD) Clinical Trial January 27, 2020
